- $911.09m
- $730.60m
- $100.25m
MedTech growth concerns likely to overshadow Q3 results, Leerink says
U.S. STOCKS ON THE MOVE-Robinhood, Hartford Insurance, SpaceX
U.S. STOCKS ON THE MOVE-SpaceX, Union Pacific, IBM
Diabetes device firm Beta Bionics jumps after boosted $150 mln equity raise
U.S. STOCKS ON THE MOVE-IBM, Huntington Bancshares, Meritage Homes
U.S. STOCKS ON THE MOVE-Intel, Axon Enterprise, J.B. Hunt
Diabetes device firm Beta Bionics falls on $150 mln equity raise
Brief: Beta Bionics Announces Pricing Of Public Offering Of Common Stock And Pre-Funded Warrants
Diabetes device firm Beta Bionics slides on $125 mln stock offering plans
Beta Bionics Inc reports results for the quarter ended June 30 - Earnings Summary
Beta Bionics Q2 sales beat estimates on pharmacy channel growth
Brief: Beta Bionics Inc Q2 EPS USD -0.53
Beta Bionics Q1 sales beat on PBP channel growth
Brief: Beta Bionics Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
Beta Bionics Q4 sales rise 57%
U.S. RESEARCH ROUNDUP-AMETEK, Stryker, Zimmer Biomet Holdings
Beta Bionics preliminary Q4 net sales rise
U.S. RESEARCH ROUNDUP-ATI, GoDaddy, Lyft
Brief: InspireMD Announces The Appointment Of Dan Dearen To Its Board Of Directors